ANANDA Scientific & Diabetes

The Science Behind It All...

ANANDA Scientific and Diabetes

The diabetes problem is enormous in its scope, with approximately 375 million patients worldwide and more than 550 million forecast by 2030. China alone now has 114 million diabetes patients and 200-300 million pre-diabetics (the medical stage immediately preceding diabetes in which blood sugar levels are abnormally high). Approximately 4 million people die each year from it. Diabetes represented at least $465 billion in global healthcare expenditures in 2011. Insulin injections are the principal way in which diabetes is maintained, but many patients remain infirm or are dying due to the inappropriateness of insulin for tactical and economical reasons. There exists an enormous unmet demand for cost-effective oral medicines able to control diabetes, and cannabinoids appear well suited in this purpose.

ANANDA Scientific has unique, intellectual property regarding cannabidiol (CBD)-based diabetes therapy and is pursuing professionally-refereed, science-based clinical work for bringing what it considers an improved and essential way to control diabetes into the medical market place. CBD may even help prevent diabetes.

Public Opinion has Shifted Dramatically.

So far, 23 US States and the District of Columbia have made cannabinoid use legal.

The number of Americans using cannabinoids for health-related resons exceeds 1 million and is rapidly increasing.



This growing acceptance is driven by the potential of cannabinoids, particularly CBD, to meet crucial, unmet needs for non-toxic, healthful and effective alternatives to existing therapies, to better treat serious health conditions and to otherwise safely and responsibly promote well-being.

Diabetes and chronic pain are public health nightmares for which CBD may play especially important therapeutic roles. ANANDA Scientific owns pertinent patents in this regard, and these conditions comprise enormous markets. Diabetes sufferers worldwide now number 371 million anticipated by 2030. Conservatively, about $36 billion will be spent globally in 2014 for medicine. Worldwide, 349 million people (more than 100 million in the US) suffer from chronic pain, and annual costs for pain medicine exceeds $50 billion ($20 billion in the US).